Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2001

Yamshchikov G, Thompson L, Ross W G, Galavotti H, Aquila W, Deacon D, Caldwell J, Patterson J W, Hunt D F, Slingluff C L

Abstract excerpt

The long-term survival of some patients with metastatic melanoma may be attributable in part to cellular immune responses to melanoma antigens. However, little is known about the level of CTL reactivity in vivo that is required for immunological control of tumor progression. In the present report, T-cell responses were evaluated with lymphocytes obtained from tumor-involved nodes and peripheral blood of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to CD11 Antigens

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CD8 Antigens

Share to HLA-A3 Antigen

Share to Immunologic Memory

Share to L-Selectin

Share to Leukocyte Common Antigens

Share to Lymphatic Metastasis

Source

Identifiers

PMID: 11300491

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.PMID 11300491Read ↗

Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.Semantic proximity Read ↗

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsSemantic proximity Read ↗

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.Semantic proximity Read ↗

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patientsSemantic proximity Read ↗

Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.Semantic proximity Read ↗

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.Semantic proximity Read ↗

Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.Semantic proximity Read ↗

Human tumor antigens recognized by T cells.Semantic proximity Read ↗

Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.Semantic proximity Read ↗

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma.Semantic proximity Read ↗

Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignanciesSemantic proximity Read ↗

Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.